These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23835879)

  • 1. Clinical features and independent predictors in the further development of rheumatoid arthritis in undifferentiated arthritis.
    Chen D; Li H; Liang L; Xiao Y; Xu T; Qiu Q; Lian F; Zhan Z; Ye Y; Xu H; Yang X
    Rheumatol Int; 2013 Nov; 33(11):2827-32. PubMed ID: 23835879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-MCV antibodies predict radiographic progression in Greek patients with very early (<3 months duration) rheumatoid arthritis.
    Barouta G; Katsiari CG; Alexiou I; Liaskos C; Varna A; Bogdanos DP; Germenis AE; Sakkas LI
    Clin Rheumatol; 2017 Apr; 36(4):885-894. PubMed ID: 27943044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of antibodies to cyclic citrullinated peptide in patients with early arthritis.
    Ateş A; Karaaslan Y; Aksaray S
    Clin Rheumatol; 2007 Apr; 26(4):499-504. PubMed ID: 16670828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis.
    Jansen AL; van der Horst-Bruinsma I; van Schaardenburg D; van de Stadt RJ; de Koning MH; Dijkmans BA
    J Rheumatol; 2002 Oct; 29(10):2074-6. PubMed ID: 12375314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The presence of anti-citrullinated protein antibodies (ACPA) and rheumatoid factor on patients with rheumatoid arthritis (RA) does not interfere with the chance of clinical remission in a follow-up of 3 years.
    da Mota LM; Dos Santos Neto LL; de Carvalho JF; Pereira IA; Burlingame R; Ménard HA; Laurindo IM
    Rheumatol Int; 2012 Dec; 32(12):3807-12. PubMed ID: 22187055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The likelihood of persistent arthritis increases with the level of anti-citrullinated peptide antibody and immunoglobulin M rheumatoid factor: a longitudinal study of 376 patients with very early undifferentiated arthritis.
    Mjaavatten MD; van der Heijde D; Uhlig T; Haugen AJ; Nygaard H; Sidenvall G; Helgetveit K; Kvien TK
    Arthritis Res Ther; 2010; 12(3):R76. PubMed ID: 20444271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevalence and diagnostic performance of anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: the predictive and discriminative ability of serum antibody level in recognizing rheumatoid arthritis.
    Heidari B; Firouzjahi A; Heidari P; Hajian K
    Ann Saudi Med; 2009; 29(6):467-70. PubMed ID: 19847085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and predictive value of anti-cyclic citrullinated protein antibodies for future development of rheumatoid arthritis in early undifferentiated arthritis.
    Emad Y; Shehata M; Ragab Y; Saad A; Hamza H; Abou-Zeid A
    Mod Rheumatol; 2010 Aug; 20(4):358-65. PubMed ID: 20364358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic performance of anti-cyclic citrullinated peptide and rheumatoid factor in patients with rheumatoid arthritis.
    Chang PY; Yang CT; Cheng CH; Yu KH
    Int J Rheum Dis; 2016 Sep; 19(9):880-6. PubMed ID: 25940989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA.
    Agrawal S; Misra R; Aggarwal A
    Clin Rheumatol; 2007 Feb; 26(2):201-4. PubMed ID: 16572283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis.
    Nielen MM; van der Horst AR; van Schaardenburg D; van der Horst-Bruinsma IE; van de Stadt RJ; Aarden L; Dijkmans BA; Hamann D
    Ann Rheum Dis; 2005 Aug; 64(8):1199-204. PubMed ID: 15640269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-cyclic citrullinated peptide antibodies distinguish hepatitis B virus (HBV)-associated arthropathy from concomitant rheumatoid arthritis in patients with chronic HBV infection.
    Lim MK; Sheen DH; Lee YJ; Mun YR; Park M; Shim SC
    J Rheumatol; 2009 Apr; 36(4):712-6. PubMed ID: 19286846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
    Matsui T; Shimada K; Ozawa N; Hayakawa H; Hagiwara F; Nakayama H; Sugii S; Ozawa Y; Tohma S
    J Rheumatol; 2006 Dec; 33(12):2390-7. PubMed ID: 16924694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnostic utility of anti-cyclic citrullinated peptide antibodies, matrix metalloproteinase-3, rheumatoid factor, erythrocyte sedimentation rate, and C-reactive protein in patients with erosive and non-erosive rheumatoid arthritis.
    Shovman O; Gilburd B; Zandman-Goddard G; Sherer Y; Orbach H; Gerli R; Shoenfeld Y
    Clin Dev Immunol; 2005 Sep; 12(3):197-202. PubMed ID: 16295525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis.
    Rantapää-Dahlqvist S; de Jong BA; Berglin E; Hallmans G; Wadell G; Stenlund H; Sundin U; van Venrooij WJ
    Arthritis Rheum; 2003 Oct; 48(10):2741-9. PubMed ID: 14558078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis.
    Shi J; van de Stadt LA; Levarht EW; Huizinga TW; Toes RE; Trouw LA; van Schaardenburg D
    Arthritis Rheum; 2013 Apr; 65(4):911-5. PubMed ID: 23279976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis.
    Nell VP; Machold KP; Stamm TA; Eberl G; Heinzl H; Uffmann M; Smolen JS; Steiner G
    Ann Rheum Dis; 2005 Dec; 64(12):1731-6. PubMed ID: 15878904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of patients with early arthritis without rheumatoid factor and ACPA and predictors of rheumatoid arthritis in the ESPOIR cohort.
    Mouterde G; Rincheval N; Lukas C; Daien C; Saraux A; Dieudé P; Morel J; Combe B
    Arthritis Res Ther; 2019 Jun; 21(1):140. PubMed ID: 31171038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does information on novel identified autoantibodies contribute to predicting the progression from undifferentiated arthritis to rheumatoid arthritis: a study on anti-CarP antibodies as an example.
    Boeters DM; Trouw LA; van der Helm-van Mil AHM; van Steenbergen HW
    Arthritis Res Ther; 2018 May; 20(1):94. PubMed ID: 29724250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.